Tento dokument je výňatok z webového sídla EUR-Lex
Dokument 62024TO0455(01)
Order of the President of the General Court of 26 November 2024.#Advanz Pharma Ltd v European Commission.#Interim relief – Medicinal products for human use – Orphan medicinal product for human use ‘Ocaliva – obeticholic acid’ – Revocation of a conditional marketing authorisation – Application for suspension of operation of a measure – No urgency.#Case T-455/24 R.
Beschikking van de president van het Gerecht van 26 november 2024.
Advanz Pharma Ltd tegen Europese Commissie.
Zaak T-455/24 R.
Beschikking van de president van het Gerecht van 26 november 2024.
Advanz Pharma Ltd tegen Europese Commissie.
Zaak T-455/24 R.
Identifikátor ECLI: ECLI:EU:T:2024:863